Paris-based medtech firm TISSIUM has secured a €60 million financing package to accelerate its growth. This capital is designated for the U.S. commercial rollout of its innovative nerve repair system, COAPTIUM® CONNECT. The funding will also support the advancement of its broader product pipeline for hernia and cardiovascular surgery.
Innovating Beyond Traditional Sutures
For decades, surgeons have relied on sutures for nerve repair, a method with a success rate of just over fifty percent. TISSIUM offers a groundbreaking alternative with its polymer platform developed from MIT and Harvard research. This technology aims to overcome the limitations and potential tissue damage associated with traditional needle-and-thread techniques.
The company's flagship product, COAPTIUM® CONNECT, is the only FDA-authorized sutureless system for nerve repair. It uses a small chamber and a light-cured polymer to seal nerve ends without penetration, dissolving over time. A clinical study showed all participants regained full function and were pain-free one year post-procedure.
Securing Capital for U.S. Market Entry
The €60 million financing is structured in two parts to fuel the company's strategic objectives. The first component is a €30 million Series D2 round completed in late 2025 with new and existing international investors. This brings TISSIUM's total capital raised since its inception in 2013 to over $200 million.
Complementing the equity round, TISSIUM secured a €30 million facility from the European Investment Bank. This funding will be disbursed in three tranches tied to specific commercial, clinical, and financing milestones. The company expects to draw the first €10 million tranche before the end of June 2026.
Competing in a Growing Medtech Sector
TISSIUM is entering the peripheral nerve repair market, valued at $13.4 billion in 2025 and projected to exceed $30 billion by 2033. This growth is driven by an increasing incidence of trauma and demand for more effective, atraumatic repair solutions. The company aims to capture a significant share of this expanding sector with its unique technology.
The market includes established players like Axogen and Integra LifeSciences, whose products often rely on biological materials and still require sutures. TISSIUM differentiates itself with a fully synthetic, bioresorbable polymer that avoids direct contact with the nerve's interior. This sutureless approach offers a significant advantage by minimizing potential tissue damage during the repair process.
A Platform for Future Surgical Innovation
The new capital will not only support COAPTIUM® CONNECT but also advance TISSIUM's diverse product pipeline. The company is developing ECLIPSIUM, a hernia repair product that has received an FDA Investigational Device Exemption. This demonstrates the versatility of its core polymer platform across multiple high-need surgical areas, including cardiovascular applications.
According to CEO Christophe Bancel, this financing is a pivotal milestone that validates the company's technology and strategy. He noted that support from international investors and the EIB reflects strong confidence in TISSIUM's ability to innovate. The funds provide the flexibility to execute the commercial strategy while investing in future platform growth.
With this substantial €60 million in new funding, TISSIUM is positioned to challenge conventional surgical techniques and establish a commercial presence in the United States. The successful clinical results of its first product and a promising pipeline signal a new era in tissue reconstruction. The company's execution of its commercial strategy will be critical in translating its scientific innovation into market leadership.